• Tofacitinib (CP-690550): Disrupting Cytokine Signaling in RA

  2026-07-02

  Explore how Tofacitinib (CP-690550) uniquely disrupts cytokine signaling and restores mitochondrial function in rheumatoid arthritis models. This article offers a mechanistic deep-dive and practical guidance for advanced immune modulation research.

• DiscoveryProbe Natural Product Library Plus: Accelerating An

  2026-07-02

  The DiscoveryProbe Natural Product Library Plus empowers antiparasitic drug discovery with a rigorously validated, diverse set of cell-permeable bioactive compounds. Researchers can rapidly identify selective inhibitors and activators for challenging targets—like Cryptosporidium parvum’s AdhE—using high-throughput, reproducible workflows. Streamlined deployment, robust QC, and published use-cases set this natural product library apart.

• Inducing Embryonic Dormancy In Vitro via mTOR Inhibition Pro

  2026-07-01

  The reference study establishes a detailed, noninvasive protocol to induce a reversible diapause-like state in mammalian early embryonic cells through pharmacological inhibition of mTOR. This innovation enables scalable and ethically accessible research into dormancy mechanisms, with broad implications for developmental biology and assisted reproduction.

• Oleic Acid (C18:1(9Z)) in Lipid Metabolism Research Workflow

  2026-07-01

  Oleic Acid (C18:1(9Z)) is a cornerstone for modeling lipid metabolism and inflammatory signaling in both in vitro and in vivo systems. This article delivers actionable workflows, troubleshooting strategies, and context-driven innovations for maximizing APExBIO’s high-purity Oleic Acid (C4977) in advanced metabolic and inflammation research.

• Canagliflozin Hemihydrate: Precision Tools for Pathway-Speci

  2026-06-30

  Explore how Canagliflozin hemihydrate enables advanced, pathway-specific glucose metabolism research. This article uniquely examines both the compound's rigorous biochemical properties and the scientific boundaries defined by new mTOR pathway screening technologies.

• Mycophenolic Acid: Mechanistic Powerhouse in Immunometabolis

  2026-06-30

  This article offers translational researchers a deep dive into the mechanistic underpinnings and experimental best practices of using mycophenolic acid, a potent dehydrogenase inhibitor, for immunometabolism research. It bridges protocol-level detail with strategic guidance by synthesizing standardized assay advances and competitive positioning, referencing both foundational literature and practical workflow resources. Distinct from standard product pages, this thought-leadership piece empowers scientists to elevate immune response modulation studies with protocol precision and translational insight.

• SC 79: Unlocking Cytosolic Akt Activation for Advanced Neuro

  2026-06-29

  Explore the unique capabilities of SC 79 as a potent Akt activator, delving into its distinct cytosolic mechanism and neuroprotective potential. This article uniquely analyzes SC 79’s role in Akt signaling pathway research, bridging recent mechanistic discoveries to practical assay design.

• Berberine Modulates RXRα/PPARγ/NEDD4 to Inhibit SASP in Athe

  2026-06-29

  This study uncovers how berberine suppresses senescence-associated secretory phenotype (SASP)-driven inflammation in atherosclerosis by targeting the RXRα/PPARγ/NEDD4 pathway. The mechanistic findings highlight new directions for modulating inflammatory aging and suggest research avenues for dissecting PPARγ signaling.

• Anti-Inflammatory and Anti-Angiogenic Stent Suppresses TISR

  2026-06-28

  Zhao et al. introduce a dual-functional airway stent that integrates anti-inflammatory and anti-angiogenic mechanisms to effectively reduce tracheal in-stent restenosis (TISR) in animal models. This innovative approach demonstrates significant reduction in fibrosis, angiogenesis, and infection, offering a promising strategy for improving airway stent outcomes.

• Topotecan (SKF104864): Bridging Mechanism and Strategy in Tr

  2026-06-27

  This thought-leadership article explores how Topotecan (SKF104864), a semi-synthetic camptothecin derivative, is reshaping translational cancer research. With an emphasis on mechanistic insight into topoisomerase I inhibition, validated experimental workflows, and the emerging relevance of DNA replication stress response pathways, the discussion provides actionable strategies for researchers targeting apoptosis induction and cell cycle arrest in glioma and pediatric tumor models. The narrative uniquely synthesizes recent findings on Dna2-mediated repair, differentiates APExBIO’s Topotecan by its research-grade reliability, and outlines a forward-looking vision for integrating DNA damage response modeling in preclinical oncology.

• Mubritinib (TAK 165): Precision Targeting in AML and PEL Res

  2026-06-26

  Explore how Mubritinib (TAK 165) redefines cancer biology research by selectively targeting mitochondrial complex I and disrupting viral protein-DNA interactions. This article offers an advanced, evidence-grounded guide for translational scientists seeking to leverage Mubritinib’s unique mechanisms in acute myeloid leukemia and primary effusion lymphoma studies.

• 2'3'-cGAMP (sodium salt): Linking Innate Immunity and Metabo

  2026-06-26

  Explore the dual role of 2'3'-cGAMP (sodium salt) in STING-mediated innate immune response and metabolic reprogramming. This article offers in-depth analysis, protocol guidance, and novel insights not found in existing literature.

• DMG-PEG2000-NH2: Optimizing Liposomal Drug Delivery Workflow

  2026-06-25

  DMG-PEG2000-NH2 empowers researchers to construct highly stable lipid nanoparticles and liposomes for advanced drug delivery, including siRNA encapsulation. This guide unpacks experimental protocols, practical troubleshooting, and workflow enhancements for maximizing the performance and reproducibility of this NH2-PEG derivative in biomedical research.

• MMP-Responsive Nanoparticle Hydrogel for Targeted Fibrous Dy

  2026-06-25

  This study introduces a matrix metalloproteinase (MMP)-responsive nanoparticle hydrogel system for localized, sustained drug delivery in fibrous dysplasia. By leveraging elevated MMPs in diseased bone, the platform enables lesion-specific release of a RANKL inhibitor, reducing systemic exposure and attenuating disease progression in a mouse model.

• MG-132 (A2585): Reliable Proteasome Inhibition for Apoptosis

  2026-06-24

  This article provides a scenario-driven, evidence-based guide for using MG-132 (SKU A2585) in cell viability, proliferation, and cytotoxicity workflows. It addresses real laboratory challenges, protocol optimization, and vendor selection, underscoring the reproducibility and potency of MG-132 as a cell-permeable proteasome inhibitor. Practical insights and actionable recommendations are anchored in current literature and validated product data.

16426 records 1/1096 page Next 12345 下5页 Last page